Ziftomenib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2A r and NPM1 -m AML.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
Ziftomenib (Komzifti) for acute myeloid leukemia.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026
Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.
Journal: Journal of personalized medicine
Published: February 16, 2026
Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
Journal: European journal of haematology
Published: January 29, 2026
Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care.
Journal: Cancers
Published: January 20, 2026
Menin inhibitors for adult acute myeloid leukemia: 2025 update.
Journal: Expert opinion on investigational drugs
Published: December 31, 2025
Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms.
Journal: International journal of molecular sciences
Published: December 29, 2025
The promise of menin inhibitors: from approval to triplet regimens.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Last Updated: 04/28/2026